Real-World Utilization of Lenvatinib and Pembrolizumab Combination Therapy for the Treatment of Endometrial Cancer in the USA
Future Oncology · 2024
DOI: 10.2217/fon-2023-0058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, 2024. Verfasst von Keiko Wada und 5 weiteren Autor:innen. Beteiligte Einrichtung: Real World Solutions, IQVIA Inc., Durham, NC 27703, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Endometrial Neoplasms, Quinolines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck Sharp and Dohme, Eisai Inc..
Abstract (Originalsprache)
Aim
Describe treatment and dosing patterns of lenvatinib and pembrolizumab combination therapy (lenva+pembro) among endometrial cancer (EC) patients in US clinical practice. Materials & methods: Retrospective cohort study among adults with EC initiating lenva+pembro in second line (2L) or third line and later (≥3L) between 17 September 2019 and 30 June 2021.
Results
110 patients initiated lenva+pembro in 2L and 135 patients in ≥3L. Majority of patients initiated lenva+pembro at label-recommended starting doses/interval. Less than half changed lenvatinib dose over time. At median follow-up of 7.3 and 8.7 months, median (95% CI) duration of therapy was 5.1 (4.7-6.1) and 5.8 (4.2-7.3) months for patients in 2L and ≥3L, respectively.
Conclusion
Lenva+pembro was mostly initiated at label-recommended dose. This study looked at details of lenvatinib and pembrolizumab combination treatment among patients with endometrial cancer (EC) in the USA. Specifically, these patients had received prior chemotherapy or hormone therapy before starting lenvatinib and pembrolizumab. Most patients started lenvatinib and pembrolizumab at the dose recommended by the product label and received the next pembrolizumab injection within the recommended timeframe. Over time, more than half of the patients did not change the dose of lenvatinib, and most patients had the same dose of pembrolizumab. On average, patients were treated with lenvatinib and pembrolizumab for 5–6 months. This study showed that in general, patients were taking lenvatinib and pembrolizumab for treatment of EC as recommended by product labels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Real World Solutions, IQVIA Inc., Durham, NC 27703, USA.
- Worldwide Real World Evidence (WW RWE), Eisai Inc., Nutley, NJ 07110, USA.
- Center for Observational and Real World Evidence(CORE), MRL, Merck & Co., Inc., Rahway, NJ 07065, USA.
ORCID-Profile: Inyoung Lee, Aimee Near, Vimalanand S Prabhu
Förderung
- Merck Sharp and Dohme
- Eisai Inc.
Zitieren
APA
Wada, K., Zhang, J., Lee, I., Wang, Y., Near, A., & Prabhu, V. S. (2024). Real-World Utilization of Lenvatinib and Pembrolizumab Combination Therapy for the Treatment of Endometrial Cancer in the USA. Future Oncology. https://doi.org/10.2217/fon-2023-0058
Vancouver
Wada K, Zhang J, Lee I, Wang Y, Near A, Prabhu VS. Real-World Utilization of Lenvatinib and Pembrolizumab Combination Therapy for the Treatment of Endometrial Cancer in the USA. Future Oncology. 2024. doi:10.2217/fon-2023-0058
BibTeX
@article{Wada2024,
author = {Wada, Keiko and Zhang, Jingchuan and Lee, Inyoung and Wang, Yi and Near, Aimee and Prabhu, Vimalanand S},
title = {Real-World Utilization of Lenvatinib and Pembrolizumab Combination Therapy for the Treatment of Endometrial Cancer in the USA},
journal = {Future Oncology},
year = {2024},
doi = {10.2217/fon-2023-0058}
}
EUVIMED